Cranalon™ - Clinical Trials
|I Product Info||I Ingredients||I Recommended Use||I Clinical Trials||I Research Brief||I References|
Low USA domestic & international
Indication: constipation, intestinal microflora imbalance, increased body weight, increased cholesterol levels and blood sugar levels, undue fatigue, decreased immune response, colds.
Main Actions: improves host defenses, stimulates bowel movements, works as mild laxative, promotes body cleanse, increases vitamin and mineral absorption, improves digestion, helps to normalize blood cholesterol levels, triglyceride and blood sugar levels, promotes the growth of “friendly” bacteria in the intestine.Ingredients (per 1 packet):
Fibersol 2 (Soluble Dietary Fiber) – 5,000 mg; Proprietary Blend – 410 mg: Aloe Vera gel concentrate (200:1), Cranberry (Vaccinium macrocarpon) powder, Malic acid, Phenalgin™ (phlorotannin extract of Canary Islands Brown Algae)(Cystoseira canariensis), Red Algae (Dunaliella salina).
Cranalon™ - Clinical Trials:
Fibersol 2™ is fermented slowly, thus producing less acid and gas than most soluble dietary fibers.
The left picture shows a regular absorption pattern of sugar/starch. Most of it is absorbed in the stomach. The right picture shows the process of absorption of sugar/starch with Fibersol 2™. Only a small part is digested in the stomach, the rest reaches the large intestine and is used as food for beneficial bacteria. It also normalizes the intestine microflora and increases the fecal volume.
Fibersol 2™ slows absorption that is beneficial for blood sugar level and regulates the insulin production (pic.1). It is shown that blood sugar level rise after Fibersol 2™ intake is lower (right diagram).
Helps maintain healthy blood sugar levels and subsequent insulin response.
Studies indicate that Fibersol 2™ can effectively reduce serum blood sugar levels, potentially allowing formulation to be used in foods for diabetics, weight control, and managing serum glucose before, during, and after exercise.
Helps maintain healthy levels of blood triglycerides and serum cholesterol.
Fibersol 2™ significantly reduces of blood triglycerides levels and serum cholesterol levels. Additionally, Fibersol 2™ effectively retains HDL (good) cholesterol levels. All this potentially impacts the incidence of coronary heart disease and related diseases.
Fibersol 2™ lowers serum cholesterol levels and triglyceride levels but does not reduce HDL-cholesterol levels.
Helps maintain healthy intestinal regularity.
By adding stool volume, moisture, and reducing transit time, Fibersol 2™ helps maintain good colon health, potentially reducing the incidence of various types of colon diseases. In addition, Fibersol 2™ has been shown to prevent atrophy of the lining of the large intestine and does not create excess gas associated with some soluble dietary fibers.
Helps promote the growth of beneficial bacteria in the colon.
As a water-soluble fiber, Fibersol 2™ can effectively promote the growth of a variety of beneficial bacteria (naturally occurring or ingested as probiotics) in the colon. In promoting the growth of beneficial bacteria, Fibersol 2™ indirectly reduces the presence of undesirable bacterial species.
Clinical trial (subjects: 6 males and 14 females prone to constipation) showed that after Fibersol 2™ intake the fecal frequencies increased almost twice. (4)
Fecal frequency study over a 5 day-period:
2.6 times before Fibersol 2™ intake.
4.0 times after Fibersol 2™ intake (3.75 grams/day).
More than 150 clinical trials were conducted with the purpose to determine the influence of dietary fibers on the condition of cardio-vascular system. Increased cholesterol levels are one of the major risk factors of coronary heart diseases. The findings demonstrated that soluble fiber reduces the risk of heart disease by lowering cholesterol levels and LDL. Soluble fibers decrease the bile absorption process. Bile, which contains cholesterol, is necessary for the digestion of fat. It is secreted into the intestine in response to food intake and most of it is reabsorbed after digestion is completed, when soluble fiber is present not as much bile is reabsorbed.
The Nurses’ Health Study, a large, prospective cohort study of US women followed up for 10 years from 1984. Dietary data were collected in 1984, 1986, and 1990, using a validated semiquantitative food frequency questionnaire.
A total of 68782 women aged 37 to 64 years without previously diagnosed angina, myocardial infarction (MI), stroke, cancer, hypercholesterolemia, or diabetes at baseline.
Response rate averaged 80% to 90% during the 10-year follow-up. 591 major CHD events (429 nonfatal MIs and 162 CHD deaths) were documented. The age-adjusted relative risk (RR) for major CHD events was 0.53 (95% confidence interval [CI], 0.40-0.69) for women in the highest quintile of total dietary fiber intake (median, 22.9 g/d) compared with women in the lowest quintile (median, 11.5 g/d). After controlling for age, cardiovascular risk factors, dietary factors, and multivitamin supplement use, the RR was 0.77 (95% CI, 0.57-1.04).
For a 10-g/d increase in total dietary fiber intake (the difference between the lowest and highest quintiles), the multivariate RR of total CHD events was 0.81 (95% CI, 0.66-0.99). Among different sources of dietary fiber (eg, cereal, vegetables, fruit), only cereal dietary fiber was strongly associated with a reduced risk of CHD (multivariate RR, 0.63; 95% CI, 0.49-0.81 for each 5-g/d increase in cereal dietary fiber).
CONCLUSIONS: Our findings in women support the hypothesis that higher fiber intake, particularly from cereal sources, reduces the risk of CHD. (7)
The research conducted in the Netherlands showed that men using insufficient amount of dietary fiber are four times more susceptible to fatal results of CVD. The daily dietary fiber intake should be no less than 37 mg per day.
Adequate health fiber diets add material to the waste stream, which would normalize pathological processes: increase or decrease intestinal transit time. The British scientist D. Burkitt found a direct relation between the transit time of fecal mass and the ratio of vegetable dietary fibers in the daily diet. Burkitt et al, in compared various population groups and found that those on high health fiber diets produced stools of 150- 980 grams/day, with transit times of 19-68 hours. Those on low health fiber produced stools of 39-195 grams/day with transit times of 28-144 hours. (8)
Centre for Gastroenterology, Institute of Cellular and Molecular Science, Barts and The London, Queen Mary School of Medicine and Dentistry, London, UK.
The herbal preparation, aloe vera, has been claimed to have anti inflammatory effects and, despite a lack of evidence of its therapeutic efficiency, is widely used by patients with inflammatory bowel disease. AIM: To perform a double-blind, randomized, placebo-controlled trial of the efficiency and safety of aloe vera gel for the treatment of mildly to moderately active ulcerative colitis. METHODS: Forty-four evaluable hospital out-patients were randomly given oral aloe vera gel or placebo, 100 mL twice daily for 4 weeks, in a 2 : 1 ratio.
RESULTS: Clinical remission, improvement and response occurred in nine (30%), 11 (37%) and 14 (47%), respectively, of 30 patients given aloe vera, compared with one (7%) [P = 0.09; odds ratio, 5.6 (0.6-49)], one (7%) [P = 0.06; odds ratio, 7.5 (0.9-66)] and two (14%) [P < 0.05; odds ratio, 5.3 (1.0-27)], respectively, of 14 patients taking placebo. The Simple Clinical Colitis Activity Index and histological scores decreased significantly during treatment with aloe vera (P = 0.01 and P = 0.03, respectively), but not with placebo. Adverse events were minor and similar in both groups of patients. (9)
CONCLUSION: Oral aloe vera taken for 4 weeks produced a clinical response more often than placebo; it also reduced the histological disease activity and appeared to be safe. Further evaluation of the therapeutic potential of aloe vera gel in inflammatory bowel disease is needed.
Faculty of Allied Health, Medical Laboratory Sciences, Kuwait University, P.O. Box 31470, Sulaibikhat 90805, Kuwait.
The present study was carried out to examine the anti inflammatory activity of the inner leaf gel component of Aloe barbadensis Miller. A simple in vitro assay was designed to determine the effect of the inner gel on bacterial-induced pro-inflammatory cytokine production, namely TNF-alpha and IL-1 beta, from peripheral blood leukocytes stimulated with Shigella flexneri or LPS. This report describes the suppression of both cytokines with a freeze-dried inner gel powder and a commercial health drink from the same source. Comparison was made with a human monocytic cell-line (THP-1 cells) and a similar trend in responses was demonstrated. (10)
Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Thailand.
Thirty one healthy male medical students between 18 and 23 years of age were enrolled in the clinical trial. Subjects ingested 100 g of fresh aloe gel twice a day for seven consecutive days. The 24-hr urine was collected one day prior to taking the gel (Day 0), Days 2 and 5 of consumption, and Day 8 (one day after completion).
CONCLUSION: Fresh Aloe vera gel (100 g) contains 96.3 mg of citrate and 158.9 mg of tartrate. This is mid-range for Thai fruits. Changes in chemical compositions of urine after aloe consumption shows its potential for preventing kidney stone formation among adults. (11)